Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilvegostomig + ramucirumab
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Rilvegostomig + ramucirumab** is an investigational combination of two monoclonal antibodies aimed at treating advanced or metastatic non-small cell lung cancer (NSCLC). **Rilvegostomig** (code name AZD2936) is a novel therapeutic antibody, while **ramucirumab** (brand name Cyramza) is a recombinant human IgG1 monoclonal antibody targeting VEGFR-2 to inhibit angiogenesis. The combination is designed to simultaneously target immunologic and angiogenic pathways to inhibit tumor growth and progression. This combination is currently being evaluated in clinical trials, notably in combination with platinum-based chemotherapies for NSCLC[1].
- Other names
- rilvegostomig + ramucirumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)VEGFR2 (Vascular endothelial growth factor receptor 2)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on rilvegostomig + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilvegostomig + ramucirumab.